What is the clinical efficacy and adverse effect profile of baxodrostat (oral steroid 11‑beta‑hydroxylase inhibitor) for treating endogenous Cushing's syndrome?

Baxodrostat for Cushing's Syndrome: Important Clarification

You are asking about baxodrostat, but the available evidence exclusively addresses osilodrostat—a different 11β-hydroxylase inhibitor used for Cushing's syndrome. Baxodrostat is actually an aldosterone synthase inhibitor FDA-approved for hypertension, NOT for Cushing's syndrome 1.

Critical Distinction

Baxodrostat specifically does NOT affect cortisol synthesis and is therefore not indicated for treating Cushing's syndrome 1. The FDA label explicitly states that baxodrostat has "higher potency and selectivity for aldosterone synthase compared to the closely related enzyme 11β-hydroxylase (final enzyme in cortisol synthesis)" and that it "significantly lowered aldosterone concentrations without affecting cortisol responses over a wide dose range" 1.

Key Pharmacologic Differences:

• Baxodrostat: Inhibits aldosterone synthase → lowers aldosterone → treats hypertension
• Osilodrostat: Inhibits 11β-hydroxylase → lowers cortisol → treats Cushing's syndrome

If You Meant Osilodrostat for Cushing's Syndrome

Osilodrostat is highly effective for Cushing's syndrome, achieving cortisol normalization in 53% of patients at 24 weeks with sustained control and improvements in cardiovascular, metabolic, and quality of life parameters 2.

Clinical Efficacy

Biochemical Control:

• 53% achieved complete response (UFC ≤ULN) at week 24 without dose escalation 2
• 86% maintained response during randomized withdrawal vs 29% on placebo (p<0.0001) 2
• Real-world data shows 81% achieved normal UFC at last observation, with 92% achieving it at least once 3
• Median time to first UFC normalization: 67.5 days at median dose of 5 mg/day 3

Clinical Improvements:

• Significant reductions in blood pressure (142/87 → 124/70 mmHg), enabling reduction of antihypertensives in 96% of patients 4
• Improved glycemic control: 90% of diabetic patients reduced antidiabetic medications including insulin 4
• Median clinical score decreased from 9 to 4 4
• Muscle strength increased from 50% to 75% of normal 4
• Improvements in body weight, depression, and quality of life 5

Adverse Effect Profile

Most Common Adverse Events:

• Adrenal insufficiency: 28-31% (most common, manageable with dose adjustment) 5, 6
• Nausea: 32-42% 5, 2
• Fatigue: 28-58% 5, 2
• Headache: 25-34% 5, 2
• Hypokalemia: 13-18% 5, 6
• Edema: 8% 5
• Hyperandrogenic symptoms (hirsutism 11.3%, acne 11.3%) 5

Serious Considerations:

• QT prolongation: 3.6% - requires baseline ECG, repeat within 1 week of initiation, and periodic monitoring 5
• Avoid concomitant QT-prolonging drugs (citalopram, procainamide, levofloxacin) 5
• Hypocortisolism occurred in 51% of patients 2

Practical Management Algorithm

Starting Dose:

• Standard severity: 2 mg twice daily (4 mg/day total)
• Severe disease (baseline cortisol >36 mg/dL): Consider 6 mg/day with more frequent monitoring 5

Titration:

• Adjust every 2 weeks based on UFC and safety
• Use slower up-titration to minimize adverse effects 5
• Therapeutic doses typically 4.5-6.5 mg/day (median 5 mg/day) 3, 4

Monitoring:

• UFC and morning cortisol every 2 weeks during titration
• Once stable: every 1-2 months 5
• ECG at baseline, within 1 week of initiation, then as clinically indicated 5
• Potassium, blood pressure, and signs of hypocortisolism at each visit

Managing Hypocortisolism:

• If UFC drops below normal: decrease dose or temporarily discontinue 5
• If symptoms worsen: consider low-dose, short-term glucocorticoid replacement 5
• Reinitiate at lower dose once cortisol normalizes and symptoms resolve 5

Drug Interactions:

• Decrease dose 50% with strong CYP3A4 inhibitors (ketoconazole, erythromycin) 5
• Increase dose with CYP3A4 inducers (mitotane, carbamazepine, rifampicin) 5

Common Pitfalls to Avoid

• Do not confuse baxodrostat with osilodrostat—they treat different conditions
• Do not ignore early signs of adrenal insufficiency (fatigue, nausea, weakness)—this is the most common adverse event requiring dose adjustment
• Do not skip ECG monitoring in patients with QT risk factors
• Do not forget to correct hypokalemia and hypertension before initiating therapy 5
• Counsel all patients on emergency glucocorticoid use to prevent adrenal crisis 5